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BACKGROUND: Once-weekly gemcitabine concurrent with radiotherapy was highly effective in the treatment of
head and neck cancer (HNC) but limited by high mucosal toxicity. Pre-clinical investigations suggested that
delivering gemcitabine at substantially lower doses twice weekly during radiotherapy improved the therapeutic
ratio. We sought to translated these preclinical findings to a phase I trial. METHODS: Twenty-five patients with
non-resectable HNC were scheduled to receive gemcitabine twice weekly during the last 2 weeks (total 5
infusions) of hyperfractionated radiotherapy delivering 1.2 Gy twice daily to total 76.8 Gy. Tumor biopsies to
measure active intracellular (phosphorylated) gemcitabine were planned after the first drug delivery. Patients were
assigned to escalating dose cohorts using the Continuous Reassessment Method. RESULTS: Twenty-one patients
evaluable for toxicity were divided into cohorts receiving twice weekly treatment with 10, 20, 33, or 50 mg/m2
gemcitabine. Dose-limiting toxicity was grade 3-4 confluent mucositis/pharyngitis, and the maximally tolerated
dose (MTD) was 20 mg/m2. Median survival was 20 months, with no difference between cohorts receiving lower
(10, 20 mg/m2) or higher (33, 50 mg/m2) gemcitabine doses. Tumor biopsies after the first drug delivery showed
only a minority of tumor cells in the specimens. CONCLUSION: These findings validate preclinical models that
show that gemcitabine is radiation sensitizer at doses far below those used for systemic chemotherapy. However,
the improvement in the therapeutic ratio predicted from the preclinical study did not translate into a substantial
relative increase in the MTD of the drug in the clinical phase I trial.
Translational Oncology (2014) 7, 479–483Address all correspondence to: Avraham Eisbruch, MD, Department of Radiation
Oncology, University of Michigan Hospital, 1500 EMed Ctr Dr Ann Arbor MI 48105
USA. E-mail: eisbruch@umich.edu
1This project was supported in part by NCI grants RO1 CA138723 and P30
CA047904 and the Newman Family Fund, and used the UPCI Biostatistics Facility.
2The authors report no conflict of interest. No financial disclosure is reported by any author.
3Dr. A. Popvtzer current address: Department of Radiation Oncology, Rabin Medical
Center, PetachTikva, and Sackler Faculty ofMedicine, Tel AvivUniversity, Tel Aviv, Israel.
4Dr Normolle current address: Department of Biostatistics, University of Pittsburgh, PA.
Received 6 March 2014; Revised 18 April 2014; Accepted 23 April 2014
© 2014 The Authors. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/3.0/).
1936-5233/14
http://dx.doi.org/10.1016/j.tranon.2014.04.016Introduction
Improved tumor control rates have been documented using
concurrent radiotherapy and chemotherapy in patients with
squamous cell carcinoma of the head and neck (HNC) [1,2], at the
expense of higher rates of acute and late toxicities [2–6]. Strategies to
improve these results include the development of better radio-
sensitizers and better drug-radiotherapy delivery schedules. Our
group has previously demonstrated that subcytotoxic concentrations
of gemcitabine act as radiosensitizers in cancer cells [7]. Prompted by
these findings, we conducted a phase I study in patients with
nonresectable head and neck cancer [8]. Radiotherapy was combined
with a weekly dose of gemcitabine starting at a cohort receiving
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gemcitabine monotherapy (1000-1200mg/m2/week). Although the
tumor-control rates were very encouraging, treatment led to severe
mucosal/pharyngeal toxicity warranting a dose de-escalation. Excess
toxicity, especially severe dysphagia, continued to be observed even at
weekly doses as low as 50 mg/m2/week [8,9]. We concluded that this
regimen resulted in an unsatisfactory therapeutic ratio and was
therefore not recommended for further study. Similar findings of
severe acute mucosal reactions were reported by other investigators
testing weekly gemcitabine concurrent with RT for HNC, with
recommended phase II doses of 50 or 100 mg/m2/week, representing
b 10% gemcitabine dose delivered alone [10,11].
In an attempt to improve the therapeutic ratio of concurrent
gemcitabine-radiotherapy, we tested fractionated radiotherapy concurrent
with different schedules of gemcitabine inmice implantedwith squamous
cell carcinoma [12]. Tumor eradication rate was measured vs. the main
toxicities found in the clinical study (lip mucositis and weight loss
representing acute dysphagia in mice). The highest therapeutic ratio
was achieved with a twice-weekly regimen of gemcitabine, at
substantially lower doses than in the once-weekly regimen [12]. We
have translated these results into a phase I study of gemcitabine
concurrent with RT for locoregionally advanced HNC, which is the
subject of this report.
On the basis of the preclinical study, we hypothesized that the
maximum tolerated dose (MTD) of gemcitabine administered twice
weekly concurrent with RT would be close to the MTD of the drug
delivered alone twice-weekly: 75-90mg/m2/dose [13,14], allowing
potential preservation of the tumor sensitizing properties of
gemcitabine in a better tolerated regimen.
We have employed in this study several additional strategies to
maximize the efficacy of the combined regimen. There is a theoretical
advantage of treatment intensification with chemotherapy during the
last weeks of radiotherapy, when accelerated tumor cell population
growth is thought to take place, and clinical reports support the
efficacy of such a chemotherapy “boost” [15–18]. We therefore opted
to administer the twice-weekly gemcitabine during the last 2 weeks of
the radiotherapy course. During this phase, radiation was delivered
only to the gross tumor volume, intending to minimize radio-
sensitization of the normal tissue included in target volumes of sub-
clinical disease treated prophylactically. In addition, radiotherapy was
hyperfractionated, to gain potential tumor-control advantages [19].
We report here the results of a phase I translating our pre-clinical
study, seeking the MTD of gemcitabine administered twice a week
during the last 2 weeks of a hyperfractionated RT course for loco-
regionally advanced, poor prognosis HNC.
Patients and Methods
The trial was approved by the University of Michigan Institutional
Review Board, and all patients signed Institutional Review Board–
approved informed consent.
The study group consisted of patients over 18 years of age with
biopsy-proven squamous cell carcinoma of the head and neck who
were not candidates for surgery because the tumor was considered
nonresectable by tumor-board consensus or resection was expected to
result in unacceptable functional or oncological outcomes. Other
inclusion criteria were Karnofsky status at least 70, life expectancy at
least 6 months, and adequate bone marrow, kidney, and liver
function. Patients with a history of previous head/neck radiation or
chemotherapy were excluded.Patients underwent a complete history and physical examination,
baseline assessment of organ function, documentation of tumor
location and size, and pregnancy test for premenopausal women.
Radiologic evaluation included chest x-ray, head and neck CT or
PET-CT, and in some cases, MRI.
Intensity-modulated radiotherapy (IMRT) was delivered according
to previously published methods [20]. Hyperfractionated radiother-
apy was delivered twice daily at 1.2 Gy per fraction, at least 6 hours
apart, 5 days a week. For the purposes of this protocol, IMRT was
delivered in two consecutive plans. Over the first 21 treatment days
(initial phase), 50.4 Gy was delivered to all targets in 42 twice-daily
fractions of 1.2 Gy each. On days 22-32 (radiation boost phase),
during which gemcitabine delivery was planned, an additional 26.4
Gy was delivered to the primary tumor and gross nodal CTVs
(CTV1s) at 1.2 Gy per fraction, twice daily. The total intended
CTV1 dose was 76.8 Gy, delivered over 6.5 weeks (64 fractions in 32
treatment days). Doses were prescribed to planning target volumes
consisting of 0.5 cm uniform expansions of the CTVs. Target
inhomogeneity goals were 99%-107% of the prescribed doses.
Gemcitabine was infused IV over 30 minutes. Five infusions were
planned twice weekly during the last 11 treatment days (the radiation
boost phase), at least 2 days apart.
Toxicity was graded according to the World Health Organization
(WHO) scale for hematologic toxicities and the Radiation Therapy
Oncology Group (RTOG) scale for nonhematologic toxicities. Grade
3 or 4 toxicities that did not improve to grade 2 or less within 3
months were considered dose-limiting. Late grade 3 esophageal
toxicity was considered dose-limiting if it did not improve to grade 2
or less following dilation. In the event of an acute dose-limiting
toxicity, or toxicity that required dose-holding, the scheduled
gemcitabine treatment was temporarily halted until toxicity declined
to grade 2 or less; it was then resumed at the next lower dose level.
Radiation continued without interruption unless there was grade 4
mucositis or skin desquamation that did not respond to supportive
measures. In these cases, a break in radiation treatment was allowed.
Tumor biopsies to assess the intracellular levels of dFdCTP and
dFdCDP, the active metabolites of the drug, were planned 2 hours
after the first gemcitabine infusion on day 22. The assessment
methods for intracellular phosphorylated metabolites have been
detailed previously [8].
Follow-up was conducted 4 weeks after completion of therapy,
including clinical assessment for toxicity, history and physical
examination, laboratory evaluation of liver and kidney function and
complete blood count. Thereafter, patients were evaluated for late
toxicity and tumor status every 2 months during the first 2 years and
then every 3 to 4 months. At 3 months after completion of treatment,
tumor response was assessed by physical examination and CT or PET
scans, in addition to direct endoscopy under anesthesia. Complete
response was defined as the disappearance of all assessable disease at
endoscopy and on images.
The trial was designed to estimate the maximally tolerated dose
(MTD), defined as the dose associated with unacceptable toxicity in
b20% of patients. Using modified Continual Reassessment Method
(CRM) [21,22], we allocated each tested dose to cohorts of at least 3
patients. The first cohort was assigned 10 mg/m2 twice weekly. After
toxicity was evaluated, the target dose was estimated from the
accumulated data, and the next cohort was assigned the next
estimated target dose (20 mg/m2 twice weekly). This was repeated for
doses of 33 and 50 mg/m2 twice weekly.
Table 2. Characteristics of Head and Neck Malignancies in 25 Patients
Tumor stage N0 N1 N2 N3
X 2
2 2
3 1 2 3
4 7 1 4 3
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be escalated only one level between cohorts. 2. Doses could be
escalated only after a minimum of 3 patients had been observed at the
next lower dose for a minimum of 4 weeks. 3. Doses could be
escalated only if no acute toxicity of grade 3 or higher was observed at
the end of the 4-week post-therapy observation period in the previous
cohort. If at least one acute toxicity of grade 4 or more was observed in
a cohort, dose escalation was held up, and the patients were
monitored for at least 3 months after completion of therapy. If, at that
time, any toxicity had not resolved to grade 2 or less, it was classified
as a DLT. Exceptions were late grade 3 skin, subcutaneous, mucosa,
or salivary gland toxicities which are expected to occur in most
patients following high-dose radiotherapy alone. Any toxicity of grade
4 or more at any time was considered a DLT.
The trial was planned to accrue 24 patients who were evaluable for
DLT. After the trial was closed, the dose-toxicity functionwas estimated
by logistic regression on all evaluable patients. The target dose was
calculated by inverting the dose-toxicity function at P(DLT)=0.2.
Overall survival is described using the Kaplan-Meier method. Data
were statistically analyzed with the SAS and R computing packages.
Results
Thirty-one patients were registered for the study from 2003 to 2007.
Three were disqualified because of an initial finding of distant
metastases (2 patients) or previous chemotherapy (1 patient), and 3
withdrew consent after accrual, for a final sample of 25 patients.
Patient and tumor characteristics are detailed in Tables 1 and 2. The
trial was aimed at patients with nonresectable squamous cell carcinoma.
Reasons for nonresectabilitywere carotid artery involvement bymetastatic
lymph nodes (16 patients), extensive infratemporal fossa and pterygoid
plate involvement (4 patients), nasopharyngeal involvement by tonsillar
cancer (3 patients), sphenoid sinus involvement (one patient), and fixed
tongue with bilateral hypoglossal nerve involvement (one patient). All
patients with oral cavity, laryngeal, or hypopharyngeal cancer and 8 of the
10 patients with oropharyngeal cancer had a history of heavy smoking
(N20 pack-years).
All 25 patients completed the chemoradiation protocol. Four were
not evaluable for DLT owing to progressing local disease (3 patients)
or death from uncontrolled diabetes 2 months after completing
treatment (one).Table 1. Patient Characteristics
Gender
Male 17
Female 8
Age, years
Median 63
Range 39-78
Karmofsky performance status no.
100 3
90 10
80 10
70 2
Tumor Site no.
oral cavity 6
orapharynx 10
larynx 3
hypopharynx 3
unknown primary 2
Maxillary sinus 1Drug therapywas delivered as intended in almost all cases.One of the 5
intended doses was omitted in each of 7 patients receiving 20mg/m2/wk,
and in 2 of the 3 patients receiving 33 mg/m2/wk, because of severe
mucositis. In 2 of 4 patients receiving 50 mg/m2/wk, the last dose was
omitted because of severe mucositis. None of 6 patients treated with 10
mg/m2/wk required a drug-dose modification. Radiation therapy was
delivered as intended to all patients, with no breaks short of holidays.
Table 3 shows the commonly observed acute and late toxicities and
the DLTs at each dose level. Confluent acute mucositis and
pharyngitis (RTOG grade 3) occurred in most patients, including
those receiving the lowest dose of gemcitabine. Hematological
toxicities occurred in only one patient. High-grade (RTOG grade 3 or
more) late pharyngeal or skin toxicities occurred in 2/6 patients
receiving 10 mg/m2 and both occurred frequently in the patients
receiving higher drug doses: 4/8 patients in the 20 mg/m2 cohort, 2/3
in the 33-mg/m2 cohort, and 3/4 in the 50-mg/m2 cohort.
DLTs were documented in 6 patients: 2/8 patients in the 20 mg/m2
cohort, 2/3 in the 33-mg/m2, and 2/4 in the 50-mg/m2 cohort. None of
the patients receiving 10mg/m2 had aDLT. The dose was escalated from
33 mg/m2/wk to 50 mg/m2/wk because the adverse events in the
33-mg/m2/wk cohort were re-graded to DLTs after the dose in the
50-mg/m2/wk cohort had already been assigned. Five of the six
patients with DLTs had mucosal and/or pharyngeal DLTs consisting of
persistent deep ulceration in non-tumor-bearing areas, or pharyngeal/
upper esophageal obstruction that could not be relieved by esophageal
dilation and required persistent gastric tube feeding. The remaining
patient had an acute hematological toxicity (low neutrophil count).
Toxicity estimates using the CRM formula (which assumes a
continuous dose-risk relationship) were 0.13 for 10 mg/m2, 0.19 for
20 mg/m2, 0.24 for 33 mg/m2, and 0.57 for 50 mg/m2. The MTD
was defined at the level of 20 mg/m2. As expected from the small
patient numbers in each cohort, the confidence intervals around these
estimates are wide. The 90% confidence interval for the probability of
a DLT at 20 mg/m2/wk was 0.04, 0.36.Table 3. Acute and Late Toxicities Associated with Various Doses of Twice-weekly Gemcitabine
Delivered during Radiotherapy
Toxicities 10mg/m2 (n=6) 20mg/m2 (n=8) 33mg/m2 (n=3) 50mg/m2 (n=4)
b2 3 4 b2 3 4 b2 3 4 b2 3 4
Acute
Hematologic 6 8 2 1 4
Mucosal 3 3 3 3 2 1 1 1 2 2
Pharyngeal 2 4 7 1 1 2 1 1 2
Skin 4 2 1 7 1 2
Larynx 6 4 4 1 2 2 2
Late
Mucosal 6 5 2 1 1 2 2 2
Pharyngeal 5 1 6 1 1 1 1 1 1 2 1
Skin 4 2 7 1 3 4
Subcutaneous 5 1 6 2 3 3 1
Larynx 6 8 3 4
Dose-limiting 0 2 2 2
Values represent number of patients.
482 RT and twice weekly gemcitabine Popovtzer et al. Translational Oncology Vol. 7, No. 4, 2014Of the 25 patients evaluable for tumor control, 15 (60%) had an
initial radiological and clinical complete response, 4 had a partial
response, and six had progressive disease. At a median follow-up of 30
months, locoregional control was maintained in 8 patients (32%).
Distant metastases developed in 10 of 18 patients who survived at
least 6 months; the most common site was the lungs. Median survival
time was 20.6 months (95% CI: 14.3,41.8), and the actuarial 2-year
survival rate was 41%. Survival was similar for patients receiving lower
(10 or 20 mg/m2) or higher (33 or 50 mg/m2) doses of gemcitabine.
Two patients in the 10-mg/m2 cohort underwent biopsies of the
residual primary tumor after the first infusion of gemcitabine on day 22.
Pathological evaluation showed that in both, the specimens were
composed ofmostly fibroblasts, with aminority consisting of interspersed
tumor cells. We concluded that measurements of gemcitabine
metabolites in the specimens taken after 4 weeks of radiation therapy
would not provide accurate information on drug accumulation in tumor
cells. Therefore, no additional biopsies were performed.
Discussion
In this study, the MTD of gemcitabine delivered twice weekly during
the final two weeks of a hyperfractionated RT course was 20 mg/m2,
representing 25% of the MTD of gemcitabine administered twice
weekly in a larger number of cycles without radiotherapy [15,16].
This percentage seems higher than previously reported by our group
for once-weekly gemcitabine concurrent with radiotherapy, where the
MTD was less than 5% of the MTD of gemcitabine monotherapy
[10]. However, this is not likely to represent a clinically meaningful
improvement in the therapeutic ratio, as the tolerable gemcitabine
doses are still too low. In our previous study, we observed undetectable
or only trace levels of intracellular tumor phosphorylated gemcitabine
following the administration of 10 mg/m2 (before radiotherapy), and
low intracellular levels of the active drug following the administration of
50 mg/m2 [10]. In the present study, these measurements could not be
repeated because at the time of gemcitabine administration, approx-
imately 4 weeks after the onset of radiotherapy, there was only a small
amount of tumor cells in the biopsy specimens. Nevertheless, our
previous findings suggest that the concentrations of the active drug in
tumors would be very low after the administration of 20 mg/m2.
Although twice-weekly administration likely results in an accumulation
of the drug in tumor cells over time, its impact would be restricted with
only 5 doses administered over the last 2 weeks of radiotherapy.
The clinical results of this study mirror the limited improvement in
the therapeutic ratio. The locoregional tumor-control rate of 32% in
the current study is close to that observed in other studies of chemo/
radiotherapy for nonresectable head and neck cancer [23,24] but
lower than the rate of 60% observed in our previous phase I study of
once weekly gemcitabine, which included patients with similarly
advanced local/regional disease [8]. In that study, the cohorts receiving
50-300mg/m2 gemcitabine demonstrated measurable tumor cell levels
of phosphorylated gemcitabine [8]. It is noteworthy that in both our
weekly and bi-weekly concurrent gemcitabine studies, the severe
toxicities consisted primarily of mucositis and late dysphagia. This
pattern was also reported by others utilizing once-weekly administration
of low-dose gemcitabine concurrent with radiotherapy [10,11].
What were the reasons for the failure to translate clinically the
improvement in the therapeutic ratio observed in the pre-clinical
study of twice- weekly gemcitabine? In the mouse model, the DLTs,
defined as lip mucositis and weight loss, analogous to the DLTs
observed clinically [12], were similar for gemcitabine 100 mg/kgtwice weekly and gemcitabine 800 mg/kg once weekly, concurrent
with radiotherapy. While being equi-toxic, the anti-tumor effect in
the pre-clinical study was higher in the twice-weekly compared with
the once-weekly regimen, as indicated by the significantly smaller
tumors at 28 days after therapy. This difference in the therapeutic
ratio in the pre-clinical study may not have been sufficient to produce
a clinically meaningful impact in patients.
Another approach to improve the therapeutic index was suggested
by Mason et al. in a preclinical study of different schedules of
gemcitabine concurrent with radiotherapy [25]. They determined
that the best ratio of tumor response to jejunal mucosal toxicity was
observed when gemcitabine was administered 24 hours before
radiotherapy. This was associated with faster post-drug recovery of
normal cells than tumor cells, providing a “window of opportunity”.
Nevertheless, the gain in the therapeutic ratios was small. Thus, we
believe that it is unlikely that modifications in the schedule of
concurrent gemcitabine-radiotherapy will substantially facilitate
higher effective drug dose delivery.
Asmucosal damage has been themajor toxicity observed in the current
as well as all other trials of gemcitabine-RT, effective mucosal protectors
may facilitate the safe delivery of higher concurrent gemcitabine doses.
The radiation protector amifostine has been suggested to reduce
bowel toxicity during gemcitabine-radiotherapy in patients with
pancreatic cancer [26], and may have a potential to improve the
therapeutic ratio in patients withHNC.However, thus far there is no
compelling evidence that it can effectively reduce mucositis during
chemo-RT regimens [27]. Other, new mucosal protectors require a
validation of their efficacy [28,29].
Several features have recently emerged as markers of good prognosis
inHNC, such as a history of no smoking, or remote smoking, in human
papillomavirus (HPV)-related oropharyngeal cancers [30]. However, all
the patients who participated in our study had advanced locoregional
disease, and most of those with primary oropharyngeal cancers were
heavy smokers. Better therapies are required for these patients.Whether
or not effective induction chemotherapy may improve the outcome in
these poor prognosis patients is not yet clear [31,32]. Recent reports that
hypoxic radiosensitizers and hypoxic cytotoxins are most effective in
patients with P16- negative tumors (prevalent in high-risk patients), are
encouraging avenues to increase local-regional tumor control, and
require validation [33]. If such radiosensitizers demonstrate improve-
ment in the therapeutic ratio, it would be feasible to administer them
concurrent with RT and with systemic-acting chemotherapy such as
cisplatin, which is not likely to be feasible together with gemcitabine
using the schedule we described. As long as radiosensitizers lack
improved therapeutic ratio, delivering full-dose chemotherapy can only
be feasible as induction pre-RT.
At the time this protocol was written and accruing patients, the
results of recent randomized studies showing that there was no benefit
for altered fractionated RT concurrent with chemotherapy compared
with standard fractionated RT concurrent with chemotherapy [34].
These results suggest that altered fractionation need not be employed
in studies of radiosensitization.
Dose escalation aiming at hypoxic or hypoperfused tumor subvolumes
whose perfusion is not increased shortly after the start of therapy is a route
which we have started to investigate in lieu of systemic hypoxic cytoxins
or radiosensitizers. This strategy relies on highly conformal radiotherapy
to reduce the extent of both the well-perfused parts of the tumor as well as
non-involved tissues irradiated to a high dose, in an effort to improve the
therapeutic ratio.
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